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Abstract 
Mitochondrial function is of particular importance in brain because of its high demand for 
energy (ATP) and efficient removal of reactive oxygen species (ROS). We developed rat 
mitochondrion-neuron focused microarray (rMNChip) and integrated bioinformatics tools 
for rapid identification of differential pathways in brain tissues. rMNChip contains 1,500 genes 
involved in mitochondrial functions, stress response, circadian rhythms and signal transduc-
tion. The bioinformatics tool includes an algorithm for computing of differentially expressed 
genes, and a database for straightforward and intuitive interpretation for microarray results. 
Our application of these tools to RNA samples derived from rat frontal cortex (FC), hip-
pocampus (HC) and hypothalamus (HT) led to the identification of differentially-expressed 
signal-transduction-bioenergenesis and neurotransmitter-synthesis pathways with a dominant 
number of genes (FC/HC = 55/6; FC/HT = 55/4) having significantly (p<0.05, FDR<10.70%) 
higher (≥1.25 fold) RNA levels in the frontal cortex than the others, strongly suggesting active 
generation of ATP and neurotransmitters and efficient removal of ROS. Thus, these tools for 
rapid and efficient identification of differential pathways in brain regions will greatly facilitate 
our systems-biological study and understanding of molecular mechanisms underlying complex 
and multifactorial neurodegenerative diseases. 
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INTRODUCTION 
Mitochondrial  function  is  of  particular  im-
portance  in  brain  because  of  its  high  energy  (ATP) 
demand.  Ninety  percent  (90%)  of  the  cell  ATP  are 
generated via mitochondrial oxidative phosphoryla-
tion  (OXPHOS).  Although  the  human  brain  repre-
sents only 2% of body weight, it receives 15% of the 
body’s  cardiac  output,  and  uses  20%  of  total  body 
oxygen. The high levels of oxygen and energy needs 
are continuous, and a brief period of deprivation may 
impair  neuron  function  and  even  result  in  neuron 
death.  In  addition,  mitochondrial  dysfunctions  are 
frequently documented as a key pathogenic factor in 
stress related mental disorders[1-3].  
Mitochondria  are  the  double-membrane- 
enclosed  intracellular  organelles  and  widely  known 
as the “energy factories” of the cell for their role in 
ATP  production  via  OXPHOS,  a  process  that  also 
produce  reactive  oxygen  species  (ROS)  as  the  by-
products.  The  high  ATP  production  in  the  neurons 
implies  an  efficient  removal  of  ROS.  Other  roles  of 
mitochondria  include  β-oxidation,  the  tricarboxylic 
acid (TCA) and urea cycles, the synthesis of steroid Int. J. Biol. Sci. 2011, 7 
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hormones and heme, calcium signaling, mitochondri-
al fission and fusion, regulation of lipid concentration 
in the mitochondrial membranes and the mitochon-
drial permeability, and control of cell cycle, survival 
and death[4;5]. Mitochondria are the only organelles 
possessing  DNA  (mtDNA)  as  well  as  transcription 
and translation machineries in the cytoplasm[6]. The 
number of mitochondria per cell varies widely from a 
single  mitochondrion  to  thousands  of  mitochondria 
per cell[7;8]. mtDNA encodes only 37 gene products; 
the  vast  majority  of  mitochondrial  proteins  are  en-
coded by the nuclear DNA (nDNA), synthesized by 
ribosomes  in  the  cytoplasm,  and  imported  into  the 
organelles[9].  The  highly  integrated  cross- 
functionality between nuclear and mitochondrial ge-
nomes is essential for maintenance of cellular homeo-
stasis. Defects and abnormal expression of mitochon-
dria-focused genes are correlated to rare disease (e.g., 
Leigh  syndrome  and  lethal  infantile  cardiomyopa-
thy)[10;11] and are also recognized in common dis-
eases, such as neurodegeneration, aging, cancer, obe-
sity and diabetes[12-14].  
Here, we described the development of rat mi-
tochondrion-neuron  focused  oligonucleotide  micro-
array (rMNChip) and integrated bioinformatics tools. 
rMNChip  contains  the  37  mtDNA-encoded  genes, 
1,098  nDNA-encoded  and  mitochondria-related 
genes[15],  and  365  nDNA-encoded  and  neu-
ron-related  genes,  each  in  triplicate.  The  rMNChip 
bioinformatics  tool  consists  of  an  algorithm  for  au-
thentic identification of differentially expressed genes, 
and a database for straightforward and intuitive in-
terpretation  for  microarray  results.  Applying  these 
tools for analysis of RNA samples derived from rat 
frontal  cortex  (FC),  hippocampus  (HC)  and  hypo-
thalamus (HT) led to rapid identification of the inter-
related,  differentially-expressed  signal-transduction- 
bioenergenesis and  neurotransmitter-synthesis path-
ways between the frontal cortex and the hippocampus 
or hypothalamus. Thus, the rMNChip and integrated 
bioinformatics tools are useful for rapid identification 
of  differential  pathways  and  will  facilitate  our  sys-
tems-biologic study and understanding of molecular 
mechanisms  underlying  complex  and  multifactorial 
neurodegenerative diseases. 
MATERIALS and METHODS 
Gene  selection,  oligonucleotide  design  and 
preparation: rMNChip contains 1,500 genes including 
37  mitochondrial  DNA  (mtDNA)-encoded  genes, 
1,098 nuclear DNA (nDNA)-encoded and mitochon-
dria-focused genes[15], and 365 neuron-related genes. 
These 365 genes were derived by searching the NCBI 
database (www.ncbi.nlm.nih.gov/gene) using the key 
words:  fear  response,  circadian  rhythms  and  signal 
transduction.  The  oligonucleotides  were  designed 
from  the  full  length  mRNA  sequences  as  the  tem-
plates  by  using  the  software  MacVector  v10.6.0 
(MacVector).  The  criteria  for  selecting  oligonucleo-
tides included 50 nucleotides in length (50-mer), ab-
sence  of  hairpin  structures  in  the  sequence,  45-55 
percent  of  G+C  contents  and  a  Tm  higher  than 
65oC[16].  An  amino-C6  was  added  to  the  5’  end  of 
each probe to enhance binding of the DNA to glass 
slides and accessibility for hybridization with target 
DNA.  5’-amino-C6  modified  50-mers  were  synthe-
sized and extracted to high purity by a commercial 
service (Eurofins MWG Operon).  
Microarray  design  and  fabrication:  The  1,500 
test  genes  (including  80  “housekeeping”  genes  as 
positive  control)  and  36  negative  controls  (non  rat 
DNA)  were  printed,  each  in  triplicates,  onto  the 
N-hydroxysuccinimide  ester  reactive  groups-coated 
glass  slides  (CodeLink  Activated  Slide,  SurModics, 
Eden  Prairie,  Minnesota).  DNA  probes  in  the  print 
buffer (50 mM sodium phosphate) at  the final con-
centration of 20 M of 5’-amino-C6 modified 50-mers 
were  printed  in  the  Class  100  super-clean  environ-
ment  as  described  previously[15;17;18],  using 
100-micron pins and the GeneMachine OmniGrid 100 
Microarrayer (Genomic Solutions, Ann Arbor, MI). 
Microarray labeling and hybridization, image 
scanning and processing: RNA samples of rat brain 
tissues were purchased from Zyagen (San Diego, Cal-
ifornia). One microgram RNA per sample was used 
for Cy5-dUTP (Enzo Life Sciences, Plymouth Meeting, 
Pennsylvania) labeling of cDNA. The cDNA synthesis 
and microarray hybridization were carried out by use 
of the express array detection kit (3DNA Array 900, 
Genisphere,  Hatfield,  Pennsylvania)  following  the 
manufacturer’s instructions. Slides were scanned us-
ing the ScanArray Microarray Scanner (PerkinElmer) 
at 90% laser power, 68 PMT voltages, 5 micron reso-
lution and LOWESS method. Microarray images were 
quantified by use of the rMNChip gene array list file. 
In the digitized data, each scanned spot was labeled 
by a flag either as “0” (found but not good), “1” (not 
found),  “2”  (absent),  “3”  (good),  or  “4”  (bad).  The 
“good” spots were defined by the scanner software 
setups as the spot with a calculated footprint <100 m.  
Database and data analysis: A database includes 
individual  and  relational  expression  files,  and  rela-
tional  and  category  bioinformation  files  were  com-
piled  with  the  software  FileMaker  Pro  (FileMaker, 
Inc.,  Santa  Clara,  CA)  as  described  previously[15]. 
Microarray  data  were  filtered  within  the  database 
using the following criteria: (i) test gene spots, being 
included for further analysis; (ii) spot flag = 0 or 2, Int. J. Biol. Sci. 2011, 7 
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being removed; spot flag = 1, being removed if it oc-
curs in all samples; spot flag = 3, being included; spot 
flag = 4, being removed; and (iii) signal to noise ratio 
(i.e.,  spot  mean  pixel  intensity  minus  background 
mean pixel intensity and then divided by background 
standard deviation) ≥1 in all genes and samples. To 
normalize spot data, the background-subtracted mean 
intensities  of  a  spot  were  multiplied  by  the  corre-
sponding  spot  area  ([diameter÷2]2  π)  and  then,  the 
resultant values were divided by a common area with 
the spot diameter of 100 microns. Data were normal-
ized across all intra- and inter-slide spots and array 
experiments,  and  then  used  for  the  calculation  of 
means, standard deviations, fold changes, moderated 
p values and false discovery rates (FDR).  
Gene bioinformation: Gene IDs, official symbols 
and names were downloaded from the NCBI database 
(www.ncbi.nlm.nih.gov/gene).  Ontology  (molecular 
function, biological process, and cellular component), 
phenotype (genetic disorder), Kyoto Encyclopedia of 
Genes  and  Genomes  (KEGG)  pathways  and  Online 
Mendelian  Inheritance  in  Man  (OMIM)  were  from 
DAVID Bioinformatics Resources (http://david.abcc. 
ncifcrf.gov). Drug targets associated with gene prod-
ucts  were  from  PharmGKB  pharmacogenomics 
knowledge  base  (http://www.pharmgkb.org/ 
search/index.jsp).  
Statistics:  The  quantile  normalization  method 
(27) in software R/Bioconductor version 2.7.1 (The R 
Foundation  for  Statistical  Computing)  was  used  to 
normalize data. Means, standard deviations and fold 
changes were calculated from triplicate experiments 
using XLSTAT 2006 (XLSTAT, New York, NY, USA). 
Differentially  expressed  genes  were  identified  arbi-
trarily as having a ≥1.25-fold change in the average 
expression of the background-subtracted mean inten-
sity ratios of a gene between comparisons. The mod-
erated  p-values  and  false  discovery  rate  (FDR)  for 
multiple  statistical  testing  with  Benjamini  and 
Hochberg  methods  [19]  were  calculated  with  the 
software R/Bioconductor. The level of statistical sig-
nificance  was  set  at  a  p-value  <0.05  with  a  specific 
FDR indicated. 
RESULTS 
Fifteen hundred genes and oligonucleotide 
probes on rMNChip 
rMNChip contains 1,500 rat genes, consisting of 
37 mtDNA-encoded genes, 1,098 nDNA-encoded and 
mitochondrial structure- and function-related genes, 
and 365 genes relevant to stress response, circadian 
rhythms and signal transduction. Our gene bioinfor-
matic  analysis  of  these  1,500  genes  revealed  1,109 
molecular functions associated with 1,394 genes, 2,558 
biological  processes  with  1,309  genes,  439  cellular 
components with 1,334 genes, 180 canonical pathways 
with 838 genes, 705 OMIM-associated diseases with 
397  genes,  and  941  drugs  and/or  chemical  com-
pounds with 524 genes (Table 1). Using the uniform 
criteria,  we  designed  1,500  probes  of  5’-amino-C6 
modified 50-mers and created the rMNChip microar-
rays. Supplementary Material: Table S1 lists 1500 rat 
gene ID, the official gene symbols, and the probe se-
quences.  
Table 1. Bioinformation of 1,500 Genes on rMNChip Gene Chip 
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Uniform spot shape, low background, and high 
signal-to-noise ratio of rMNChip microarrays 
The rMNChip quality was assessed by microar-
ray  experiments  with  technical  and  experimental 
triplicates  using  RNA  samples  of  rat  frontal  cortex, 
hippocampus, hypothalamus, cerebrum and cerebel-
lum. The microarray images showed a uniform spot 
shape,  low  background  intensities,  high  sig-
nal-to-noise ratios and overall consistent signal inten-
sities  on  hybridized  chips  (Fig.  1).  Specifically,  the 
diameters of 108 negative control, 240 positive con-
trol,  111  mtDNA-encoded  gene  and  4,149 
nDNA-encoded  gene  spots  were  99.88±0.33, 
118.44±2.04,  118.12±2.17,  and  117.20±2.21  microns, 
respectively.  The  corresponding  back-
ground-subtracted  mean  pixel  intensities  were 
9.95±29.07,  5017.37±1141.38,  5516.82±1487.24,  and 
5293.43±1258.56, respectively. On average, the signal 
intensities  of  mtDNA-encoded  gene  spots  (5516.82 
units  per  pixel)  and  nDNA-encoded  gene  spots 
(5293.43  units  per  pixel)  were  554.5-fold  and 
532.0-fold higher than those of the  negative control 
(9.95  units  per  pixel),  respectively.  The  mean  sig-
nal-to-noise  ratios  of  the  negative  control,  positive 
control,  mtDNA-encoded  and  nDNA-encoded  gene 
spots  were  2.33±0.31,  14.07±1.45,  15.70±1.98,  and 
15.17±1.83, respectively. The differences between the 
test genes or positive controls and the negative con-
trols  were all highly significant (p <0.0001). In con-
trast,  the  differences  among  the  positive  controls, 
mtDNA- and nDNA-encoded genes were not statis-
tically significant (p >0.05), as expected (Fig. 1).  
 
 
Fig. 1. High quality rMNChip microarray. (A) Representative microarray image of rMNChip. This pseudo-colored 
image represents an rMNChip microarray hybridized with the Cy5-labeled target cDNA reverse-transcribed from a rat 
brain RNA sample. Eight printing pinss were used to print 8 sub-arrays of rMNChip and each element was printed as a spot 
of technical triplicates adjacent to each other. The pixel intensities on spotted probes reflect abundances of hybridized target 
cDNA. (B) The inset shows details of spots morphologies of 12 genes (36 spots) with signal intensities ranging from high, to 
low and undetectable. (C) A table summarizes information of the genes and spots in the negative controls, positive controls, 
mtDNA- and nDNA-encoded test genes. The differences between the negative control and the others were highly signif-
icant (p<0.0001) while the difference between the positive control and the test spots were not statistically significant 
(p>0.05), as expected. Int. J. Biol. Sci. 2011, 7 
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Consistent intra- and inter-chip results 
The consistency between rMNChip microarrays 
was  evaluated  by  two-by-two  comparisons  of  the 
normalized (but not log transformed) mean pixel in-
tensities between the same rMNChip spots (intra-chip 
comparison)  and  between  the  different  rMNChip 
spots (inter-chip comparison) hybridized with cDNA 
labeled  using  the  same  RNA  samples.  Our  results 
revealed  high  similarities  between  the  comparisons 
(Fig.2A). Specifically, when one set of genes (Array 1) 
was compared with another (Array 2), a linear rela-
tionship of y=0.977x + 0.017 and a coefficient of de-
termination  of  r2=0.955,  were  obtained  on  a  scatter 
plot of the normalized mean pixel intensities between 
the comparison. A linear relationship of y=0.965x + 
0.026 and the coefficient of determination of r2=0.932 
were found in the comparison between Arrays 4 and 
5. In the case of the inter-chip comparison, a linear 
relationship of y=0.943x + 0.043 and the coefficient of 
determination of r2=0.887 were derived (Fig. 2A). 
 
Fig. 2. Consistency of the rMNChip microarrays and data normalization. (A) The consistency in gene expression 
levels between the intra and inter rMNChip microarrays hybridized with the same RNA sample. A scatter plot and fitted line 
of signal intensities of 1,465 informative genes between two sets of genes on Array 1 and Array 2 on Slide 1 (left panel) and 
Array 4 and Array 5 on Slide 2 (middle panel), and between two different rMNChip microarrays (right panel). Each array was 
hybridized with Cy5-labeled cDNA sample synthesized from the same RNA samples via parallel microarray experiments. 
The normalized (but not log-transformed) signal intensities of 1,465 informative genes from one were plotted against those 
of the other. The strong linear relationship (y = ax + b) and the positive coefficient of determination (r
2) were computed 
from the scatter plots and indicated in each comparison. “x”: signal intensity of a spot on one microarray, “y”: signal intensity 
of the corresponding spot on the other microarray. (B) Box plots of expression data before and after normalization. The 
quantile normalization algorithms were used to adjust the values of the background-subtracted mean pixel intensities of each 
and every set of 4,395 spots across intra- and inter- rMNChip microarrays hybridized with Cy5-labeled RNA samples 
indicated. In contrast to the boxplot of pre-normalization data (top panel), the post-normalized data distributes in the same 
intervals with the same density center, indicating successful adjustment of data. The post-normalized data were used for 
further analysis. Ln: the natural logarithm, Tis: brain tissue, Exp: microarray experiments including technical and experi-
mental triplicates, CL: cerebellum, CR: cerebrum, FC: frontal cortex, HC: hippocampus, and HT: hypothalamus. Int. J. Biol. Sci. 2011, 7 
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rMNChip computing procedures for identifica-
tion of differentially expressed genes 
The  customized  computational  procedures  in-
clude  microarray  image  evaluation,  data  filtering, 
spot  size  correction,  inclusion,  normalization  and 
comparison. Microarray image evaluation is aimed at 
revealing  image  quality  including  background,  sig-
nal-to-noise  ratio,  and  overall  consistent  spot  pixel 
intensities.  An  image  with  a  uniformly  low  back-
ground, high  signal-to-noise ratios and overall con-
sistency is used for data acquisition. Data filtering is 
aimed at removing data that may lead to false posi-
tives  or  negatives.  Spot  size  correction  is  aimed  at 
normalizing spot signal intensities; spot sizes need to 
be normalized because a spot’s area changes slightly 
as the hybridized signal intensities do. Data inclusion 
is aimed at determining whether all spots passing the 
data filtering should be used for further analysis. Be-
cause not all 9 spots per gene per sample (i.e., tripli-
cate  spots/chip  and  triplicate  experiments/sample) 
may  pass  the  filter  criteria,  inclusion  of  genes  with 
fewer  than  9  spots  per  gene  may  complicate  data 
analysis due to the missing spots. Alternatively, one 
may choose to include only genes with all the 9 spots 
fulfilling the filtering criteria for further analysis, but 
the  number  of  genes  in  the  final  result  may  be  re-
duced. 
Data  normalization  is  aimed  at  removing 
non-biological variations that can arise in any step of 
microarray experiments, such as array printing, RNA 
preparation, labeling, hybridization, or scanning[20]. 
Before  and  after  performing  quantile  normaliza-
tion[21], the pixel intensities of 65,925 spots (i.e., trip-
licate spots/gene/chip, of 1465 genes included, from 
triplicate  array  experiments,  performed  on  five  rat 
brain tissue samples) were transformed into the nat-
ural log. The transformed values were plotted as the 
boxplots to visualize successful adjustment of the data 
(Fig. 2B).  
Data  comparison  is  aimed  at  computing  the 
means,  standard  deviations,  fold  changes,  p-values 
and FDR of the normalized gene pixel intensities be-
tween desired comparisons, in order to reveal differ-
entially  expressed  genes.  Significantly  differentially 
expressed genes between the frontal cortex and the 
hippocampus or hypothalamus, and between hippo-
campus  and  hypothalamus  were  presented  as  the 
supplementary  data  (See  Supplementary  Material: 
Table S2, Table S3 and Table S4). The cerebrum and 
cerebellum  contain  a  numerous  brain  regions  and 
their data were not further analyzed. 
rMNChip database 
The  rMNChip  database  was  built  to  expedite 
data analysis and interpretation of results. Figure 3A 
shows  a  user  interface  of  the  rMNChip  database; 
Figure 3B and 3C show the linked canonical pathway 
and drug webpages viewable by clicking the Entrez 
“L” or the PharmGKB “L” on the user interface. The 
user-interface allows importing, searching, browsing, 
comparing, displaying, and exporting of (i) genes of 
interest, with the associated expression changes and 
canonical pathways, (ii) expression changes of inter-
est,  with  the  associated  genes  and  canonical  path-
ways, and (iii) canonical  pathways  of interest,  with 
the  associated  genes  and  expression  results. 
Pre-linked with the NCBI Entrez gene database and 
the  PharmGKB  drug  database  is  for  conveniently 
updating gene information.  
Differential signal-transduction-bioenergenesis 
and neurotransmitter-synthesis pathways 
To identify differential pathways, we browse the 
regulatory  (signal  transduction),  carbohydrate  and 
fatty acid metabolisms, TCA cycle, OXPHOS, REDOX, 
protein  and  neurotransmitter  synthesis  pathways 
together  with  the  associated  genes  within  the 
rMNChip database. Our results showed the pathways 
including glycolysis/gluconeogenesis (ADH1, ADH6, 
ALDH2, ALDO, DLAT, GAPDH and HK2), the TCA 
cycle (CS,DLAT, FH1, IDH3A, IDH3G, OGDH, PDK2, 
SDHA,  SDHB,  SDHC  and  SUCLA2),  fatty acid  me-
tabolism (ACAA2, ACAT1, ACSL3, ACSL4, ACSL6, 
ADH1, ADH6, ALDH2, CPT1A, ECHS1, EHHADH, 
PECI  and  SLC25A29,),  OXPHOS  (ATP5D,  ATP5E, 
ATP5I, ATP5O, ATP6V1E1, ATPAF2, COX15, COX17, 
COX18, COX6C, COX7A2, MIPEP, mt-ATP8, mt-ND1, 
NDUFA1,  NDUFA10,  NDUFA4,  NDUFAB1, 
NDUFAF1,  NDUFB10,  NDUFB4L1,  NDUFS1, 
NDUFS2, NDUFV1, PPA2, SDHA, SDHB, SDHC and 
UQCRFS1), REDOX (GPX1, GSTZ1 and PRDX1), and 
neurotransmitter  production  and  transport  (ABAT, 
AGXT,  CAD,  DDC,  GAD1,  GLS2,  GLUD1,  GPT, 
SLC25A18 and SLC25A22). The regulatory pathways 
include  insulin  signaling  (ELK1,  GRB2,  HK2, 
MAP2K2, MKNK1, PIK3CB, PIK3R3, PRKAR2A and 
PRKAR2B)  and  peroxisome  proliferator-activated 
receptor  delta  (PPARD)  signaling  (ACSL3,  ACSL4, 
ACSL6, APOA1, CPT1A, EHHADH, FABP3, FABP4, 
HMGCS2,  PPARD,  RXRA,  SCP2  and  SLC27A2).  In 
protein  synthesis  pathways,  34  genes  (MRPL1, 
MRPL14,  MRPL16,  MRPL2,  MRPL21,  MRPL23, 
MRPL28,  MRPL30,  MRPL34,  MRPL4,  MRPL40, 
MRPL43,  MRPL45,  MRPL48,  MRPL52,  MRPL53, 
MRPS18A,  MRPS25,  MRPS27,  MRPS31,  MRPS34, 
MRPS36, mt-RNR1, mt -RNR2, mt –TC, mt –TF, mt 
–TI, mt –TK, mt -TL1, mt –TN, mt –TQ, mt –TR, mt 
–TV  and  mt  –TW)  were  expressed  differentially Int. J. Biol. Sci. 2011, 7 
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among  the  frontal  cortex,  hippocampus,  and  hypo-
thalamus  (Table  2).  The  integrated  map  of  these 
pathways revealed an overwhelming number of the 
genes that were expressed significantly higher in the 
frontal cortex than in either the hippocampus (55 vs. 6, 
Fig. 4) or the hypothalamus (55 vs. 4, Fig. 5).  
 
 
Fig. 3. rMNChip database compiled in FileMaker Pro including individual expression files, gene information files and a 
relational expression file. Individual expression files keep raw microarray data imported from a microarray image and is 
linked with the relational expression file via index (a unique numerical ID to each spot on rMNChip). A gene information file 
keeps gene biological information, for example, canonical pathways and drug targets of genes. A relational expression file 
contains information on probes, array design, expression data and comparison, gene symbols and full names, and direct-links 
with the NCBI Entrez Gene Ontology and the PharmaGKB drugs and drug targets as indicated here. (A) A user-interface of 
relational gene information file displaying microarray probes, gene ID, official gene symbols and full names, gene expression 
comparisons and statistics, pathways, drugs and drug targets, as well as direct-links via gene IDs to the NCBI Entrez Gene 
website and the PharmaGKB for instantly checking or updating information. (B) An example of linking of dopa decarboxilase 
(Ddc) to the NCBI Entrez Gene KEGG pathways. (C) An example of linking of Ddc to the PharmGKB drugs. The rMNChip 
databases allow searching, browsing, displaying, modifying, updating and exporting information. Int. J. Biol. Sci. 2011, 7 
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Fig.  4.  Bioenergenesis  neurotransmitter  pathways  with  differentially  expressed  genes  between  frontal 
cortex and hippocampus. A solid line with arrowhead indicates a direct reaction or transport. A dashed line with ar-
rowhead indicates more than one steps involved in passages. The RNA levels of genes in red or green colors were expressed 
significantly higher or lower in the frontal cortex than in hippocampus, respectively. If the changes in RNA levels were not 
significant (p>0.05) or less than 1.25-fold, the gene symbols or enzymes are not shown in the flow chat. The mean expression 
levels, standard deviations, fold changes, p-values, false discovery rate (FDR) and the full name of genes are listed in Table 2. 
(A) Bioenergenesis neurotransmitter pathways include glycolysis, fatty acid synthesis, and neurotransmitter synthesis in 
cytoplasm and -oxidation, TCA cycle and OXPHOS, REDOX, and neurotransmitter synthesis in mitochondria. Double 
dashed lines represent the inner and outer mitochondrial membranes, of which a portion was enlarged to illustrate 
OXPHOS complexes I, II, III, IV and V with differentially expressed genes in each complex. A proton (H
+) flow and ATP 
synthesis are indicated. REDOX enzymes (GPX1, GSTZ1 and PRDX1) are involved in removal of ROS (e.g. O2
-). Mito-Int. J. Biol. Sci. 2011, 7 
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chondrial and cytoplasmic enzymes with RNA levels higher in the frontal cortex than in hippocampus for synthesis of 
neurotransmitters (gray ovals) include Glud1 for synthesis of the most abundant excitatory neurotransmitter L-glutamate, 
GAD1 and ABAT for the most abundant inhibitory neurotransmitter -aminobutyric acid [GABA], DDC for dopamine, 
histamine  and  serotonin,  and  AGXT  for  serine  and  glycine.  SLC25A18  and  SLC25A22  are  involved  in  transport  of 
L-glutamate across mitochondrial membranes. (B) Insulin signaling pathway. Insulin binding to its receptor results in the 
tyrosine phosphorylation of insulin receptor substrates. This leads to activation of phosphoinositide-3-kinase (PIK3CB) and 
growth factor receptor-bound protein (GRB2). These in turn lead to upregulation of insulin-responsive genes including 
hexokinase 2 (HK2) and MAP kinase interacting serine/threonine kinase 1 (MKNK1). HK2 at the outer mitochondrial 
membrane phosphorylates glucose into glucose-6-phosphate, the first rate-limiting step of glycolysis pathway. MKNK1 in 
cytoplasm phosphorylates the eukaryotic translation initiation factor (EEIF4E) initiating protein synthesis, of which 18 of 25 
genes displayed RNA levels higher in the frontal cortex than in hippocampus (Table 2). MKNK1 also modifies proteins 
posttranslationally. ELK1 member of ETS oncogene family (ELK1) plays a critical role in mitogen growth factor signal 
transduction, and its downregulation suggests decreased activities in proliferation and differentiation. (C) PPARD signaling 
pathway. Peroxisome proliferator-activated receptor delta (PPARD) is a nuclear hormone receptor and transcriptional 
regulator. Retinoid X receptor alpha (RXRA) is a steroid and thyroid hormone receptor and transcriptional regulator. Both 
PPARD and RXRA are involved in fatty acid transport and oxidation via binding to DNA and regulating transcription.  
 
 
Table 2. Pathways and Differentially Expressed Genes between Frontal Cortex and Hippocampus and between Frontal 
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Fig.  5.  Bioenergenesis  neurotransmitter  pathways  with  differentially  expressed  genes  between  frontal 
cortex and hypothalamus. A solid line with arrowhead indicates a direct reaction or transport. A dashed line with 
arrowhead indicates more than one steps involved in passages. The RNA levels of genes in red or green colors were ex-
pressed significantly higher or lower in the frontal cortex than in hypothalamus, respectively. If the changes in RNA levels 
were not significant (p>0.05) or less than 1.25-fold, the gene symbols or enzymes are not shown in the flow chat. The mean 
expression levels, standard deviations, fold changes, p-values, false discovery rate (FDR) and the full name of genes are listed 
in Table 2. (A) Bioenergenesis neurotransmitter pathways include glycolysis, fatty acid synthesis, and neurotransmitter 
synthesis in cytoplasm and -oxidation, TCA cycle and OXPHOS, REDOX, and neurotransmitter synthesis in mitochondria. 
Double dashed lines represent the inner and outer mitochondrial membranes, of which a portion was enlarged to illustrate 
OXPHOS complexes I, II, III, IV and V with differentially expressed genes in each complex. A proton (H
+) flow and ATP 
synthesis are indicated. REDOX enzyme (GSTZ1) is involved in removal of ROS (e.g. O2
-). Mitochondrial and cytoplasmic Int. J. Biol. Sci. 2011, 7 
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enzymes with the RNA levels higher in the frontal cortex than in hypothalamus for synthesis of neurotransmitters (gray 
ovals) include GLS2 and GPT for synthesis of the most abundant excitatory neurotransmitter L-glutamate, GAD1 and ABAT 
for the most abundant inhibitory neurotransmitter -aminobutyric acid [GABA], DDC for dopamine, histamine and ser-
otonin, and AGXT for serine and glycine. SLC25A18 and SLC25A22 are involved in transport of L-glutamate across mi-
tochondrial membranes. (B) Insulin signaling pathway. Insulin binding to its receptor results in the tyrosine phosphorylation 
of insulin receptor substrates. This leads to activation of phosphoinositide-3-kinase (PIK3CB and PIK3R3) and growth factor 
receptor-bound protein (GRB2). The activated PIK3CB and PIK3R3 lead to upregulation insulin-responsive genes including 
hexokinase  2  (HK2).  HK2  localizes  to  the  outer  mitochondrial  membrane  and  phosphorylates  glucose  into  glu-
cose-6-phosphate, the first rate-limiting step of glycolysis pathway. PIK3CB and PIK3R3 also activate protein synthesis, of 
which 22 of 23 genes displayed RNA levels higher in the frontal cortex than in hypothalamus (Table 1). Mitogen-activated 
protein kinase kinase (MAP2K2) plays a critical role in mitogen growth factor signal transduction, and its downregulation 
suggests decreased activities in transferring the GRB2 signal for proliferation and differentiation. (C) PPARD signaling 
pathway. Peroxisome proliferator-activated receptor delta (PPARD) is a nuclear hormone receptor and transcriptional 
regulator and is involved in fatty acid transport and oxidation via binding to DNA and regulating transcription. 
 
DISCUSSION 
Microarray  and  bioinformatics  analysis  of  the 
entire mitochondrial transcriptomes is of importance 
in  the  systems-biological  study  of  mitochondrial 
functions, especially, of the brain because of its high 
demand for energy. High level production of ATP in 
brain neurons requires accurate regulation of bioen-
ergenesis pathways to maintain physiological home-
ostasis including appropriate disposal of ROS. Oth-
erwise,  overproduction  of  ROS  (oxidative  stress)  as 
inevitable byproducts of the highly active ATP syn-
thesis may become an endogenous pathogenic or toxic 
factor  damaging  neuron  function  and  survival,  a 
characteristics  of  neurodegenerative  diseases[22;23]. 
Previously,  our  laboratory  and  other  groups  have 
developed human and mouse mitochondria-focused 
microarrays  and  bioinformatics  tools  for  expression 
profiling,  including  hMitChip2[24],  hMitChip3[15], 
h-MitoArray[25],  HuMOTIchip[26],  and  mouse  Mi-
toChips[27;28]. These customized gene chips and bi-
oinformatics tools facilitated hypothesis-driven stud-
ies of human diseases such as glucocorticoid-induced 
transcriptional  adaptations  and  MAO-A-mediated 
oxidative stress[29], proliferation rates of human ma-
lignant melanoma (MM) cells [15], molecular mecha-
nisms underlying survival-apoptosis of human MM 
cells[30],  expression  profiles  of  survival-apoptosis 
genes  in  human  MM[31],  candidate  biomarkers  in 
postmortem  brain  tissues  of  patients  with  posttrau-
matic stress disorder (PTSD)[3], ANT1-mediated reg-
ulation of mouse oxidative phosphorylation, antioxi-
dant, and apoptotic genes [28], and mouse mitochon-
drial  involvement  in  drug-induced  toxicities[27]. 
rMNChip reported here is, to our knowledge, the first 
customized  mitochondrion-neuron  focused  microar-
ray  with  its  integrated  bioinformatics  tools  for  the 
systems-biological study of neurodegeneration in rat 
models.  
Unlike  other  mitochondrial  microarrays[32], 
rMNChip  was  designed  specifically  for  study  of 
neurodegenerative diseases. First, rMNChip contains 
1,135 rat genes homologous to all the known human 
mitochondrial  genes[15]  and  365  genes  relevant  to 
stress response, circadian rhythms and signal trans-
duction.  Second,  the  rMNChip  algorithms  reduce 
non-random variance. Third, as a focused microarray, 
rMNChip is particularly useful for hypothesis-driven 
experiments.  Most  importantly,  the  rMNChip  soft-
ware greatly simplifies microarray data analysis and 
allows  rapid  identification  of  differential  pathways 
rather than only a list of the differentially expressed 
genes,  offering  straightforward  and  intuitive  inter-
pretation for microarray results. Moreover, the pros 
and cons of a customized gene chip versus a generic 
gene chip with whole transcriptomes of a species are 
described previously[15]. It is also worth mentioning 
that, in contrast to a generic gene chips with whole 
transcriptomes, the reduction of the number of genes 
makes rMNChip affordable for routinely carrying out 
microarray  experiments  with  technical  triplicates, 
experimental triplicates and biological repeats (statis-
tical  power).  These  assure  the  generation  of  repro-
ducible  and  verifiable  microarray  re-
sults[3;15;30;31;33-35].  Finally,  the  pre-link  to  the 
web-based  databases  allows  instant  update  of  the 
pathway and pharmacogenomics information. 
The high quality and consistent microarray re-
sults of rMNChip were achieved by (i) using the es-
tablished criteria for design of 50-mer oligonucleotide 
DNA probes, (ii) attaching the amino-C6 motif to the 
5’-end of each probe, (iii) printing 5’-amino-C6 modi-
fied  50-mer  probes  on  glass  slides  in  the  Class  100 
super-clean  environment,  (iv)  covalently  linking 
probes  via  5’-amino  groups  to  the 
N-hydroxysuccinimide  ester  reactive  groups  coated 
on the glass slides which allow flexible probes to ac-
cess to and hybridization with target DNA sequences, Int. J. Biol. Sci. 2011, 7 
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and (v) blocking the remaining reactive groups on the 
glass slides to reduce background. The high quality 
rMNChip was demonstrated by consistent microarray 
images and statistical analysis. 
Our results revealed 356 differentially expressed 
genes (DEGs) between the frontal cortex and hippo-
campus  (Supplementary  Material:  Table  S2),  343 
DEGs between the frontal cortex and hypothalamus 
(Supplementary Material: Table S3), but only 68 DEGs 
between the hippocampus and hypothalamus (Sup-
plementary Material: Table S4). These findings indi-
cate that the molecular differences between the frontal 
cortex  with  either  hippocampus  or  hypothalamus 
were  greater  than  those  between  hippocampus  and 
hypothalamus.  The  greater  differences  also  imply 
more  active  molecular  and  cellular  functions  of  the 
frontal  cortex  than  the  other  two.  Supporting  this 
view, the number of upregulated genes in the frontal 
cortex  is  much  greater  than  that  of  downregulated 
genes when compared with either hippocampus (FC 
vs. HC = 310 vs. 46) or hypothalamus (FC vs. HT = 315 
vs.  28).  These  results  strongly  suggest  higher  tran-
scriptional  activities  in  the  frontal  cortex  than  the 
other two brain regions. Although one might expect 
that 50% DEGs would be upregulated while the other 
50% would be downregulated, this statistical expec-
tation ought to be carefully evaluated in relationship 
to  biological  systems  under  study  and  to  a  total 
number of genes  in  measurement. In addition,  it is 
worth mentioning that the changes of many DEGs in 
these comparisons were less than 2 fold (log2-ratio of 
+/- 1). Our confidence on the resultant DEGs would 
have  been  decreased  if  without  technical  triplicates 
and experimental triplicates for the measurement of 
each and every gene on the rMNChip microarrays. 
Our application  of the rMNChip and bioinfor-
matic tools led to rapid identification of the differen-
tially expressed regulation (signal transduction), me-
tabolism,  bioenergenesis  and  neurotransmitter  bio-
synthesis pathways in rat brain tissues. These path-
ways contain an overwhelming number of the genes 
that were expressed significantly higher in the frontal 
cortex than in either the hippocampus (55 vs. 6 genes) 
or the hypothalamus (86 vs. 4). The results strongly 
suggest that the production of ATP, removal of ROS, 
and synthesis and transport of the excitatory and in-
hibitory  neurotransmitters  are  more  efficient  in  the 
frontal cortex than in the other two. The facts that the 
neurotransmitter  genes  (L-glutamate,  GABA,  dopa-
mine, serotonin, histamine, serine and glycine) were 
expressed  significantly  higher  in  the  frontal  cortex 
than in the hippocampus or hypothalamus and that 
these neurotransmitters are known to be involved in 
learning,  memory,  attention,  and  problem-solving, 
mood, appetite and sleep[36-41] implies highly active 
neuronal functions in the frontal cortex. These find-
ings are exciting and we begin to believe that the dif-
ferent  brain  regions  at  the  different  developmental 
stages  under  the  different  body-and-mind  activities 
may require the different amount of ATP and fire the 
different  amount  and  types  of  neurotransmitters. 
Thus,  rMNChip  and  software  are  useful  for  rapid 
identification  of  differential  pathways  and  facilitate 
our  systems-biological  study  and  understanding  of 
molecular mechanisms underlying complex and mul-
tifactorial neurodegenerative diseases. 
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Table S1. 1,500 rMitChip Genes and Probe Sequences.  
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Frontal Cortex (FC) and Hippocampus (HC).  
Table S3. 343 Differentially Expressed Genes between 
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